The MHRA's 2026 Peptide Inquiry: What It Covers, What It Does Not, and What Changed for Research Supply

In early April 2026 the Medicines and Healthcare products Regulatory Agency confirmed it was investigating UK clinics that promote experimental peptide injections, after press reporting found clinic websites attaching health claims to compounds that hold no UK marketing authorisation ^{[1] [2]}. The inquiry is about claims. It is not a ban, a new list of substances, or a change in the law.

This is the buyer-side reading: what was reported and when, the legal mechanism the inquiry runs on, who sits inside it, who does not, and what — if anything — it changes for laboratory supply. It stays with what the regulator and the trade press have put on the record, dated, rather than with what vendors have said about it since.

What was reported, and when

The Guardian published an investigation into UK clinics offering peptide injections at the start of April 2026. On 7 April, pharmacy trade coverage reported that the MHRA was investigating and quoted Lynda Scammell, the agency's head of borderline products ^[1]. On 15 April the aesthetics trade press carried a statement from an MHRA spokesperson on the legal position, and reported that the agency had confirmed one clinic website examined by the newspaper was making prohibited medicinal claims and that it was looking at whether statements by clinicians at a clinic amounted to medicinal claims ^[2].

The coverage named compounds including BPC-157, Cortexin and thymosin alpha, which clinic material had described in terms of tissue repair and recovery from injury, neuroprotection and cognition, and immune function ^[2]. Those descriptions are the substance of the story. The compounds themselves are not.

That last row is worth reading precisely. The MHRA publishes its advertising investigations monthly. The item titles for May, June and July 2026 concern treatment services for weight management and hay fever and several named companies; none names peptides or a peptide clinic ^[7]. That does not mean the inquiry has closed. It means no concluded peptide case has been published in that series by the date of writing, and anyone who tells you what the inquiry has found is ahead of the public record.

The legal trigger: presentation

The Human Medicines Regulations 2012 define a medicinal product in two limbs. The first covers any substance presented as having properties for treating or preventing disease in human beings; the second covers substances used or administered with a view to restoring, correcting or modifying physiological functions by pharmacological, immunological or metabolic action ^[3]. The MHRA's guidance calls the first the presentational limb and says a product may be determined to be a medicine under that limb alone ^[5].

The spokesperson's statement applied exactly that: if clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the 2012 Regulations, and the MHRA will act against clinics identified as breaching the requirements ^[2]. A product that is a medicine by presentation and has no marketing authorisation is an unauthorised medicine, and the Regulations govern its supply and advertising ^{[3] [6]}.

When deciding presentation, the agency looks at claims explicit and implicit, the overall presentation, labelling and packaging, promotional literature, testimonials, social media, and websites the product is sold on or linked to ^{[4] [5]}. Its guidance lists references to clinical research, testimonials implying medicinal claims and comparison with licensed medicines among the features that tend to make a product a medicine ^[5].

That position is not new in 2026; it restates how the classification test has always worked. The MHRA's guidance records the principle that a statement that a product is not medicinal is persuasive evidence a court may consider, but is not in itself conclusive ^[5]. What 2026 added was a public example of the principle being applied to peptides specifically, and the attribution is on the record ^[1].

Who is in scope, and who is not

The reported subjects are clinics: services offering peptide injections to members of the public with claims about what those injections do ^{[1] [2]}. The logic reaches anyone whose presentation of a peptide product amounts to a medicinal claim, because the trigger attaches to the presentation, not to the type of business.

The fourth row is not a safe harbour and should not be read as one. It describes a position that is coherent only if the supply behaves consistently with it. The published guidance is explicit that the MHRA will use a linked website, a testimonial or a referral to an article about a substance's uses as evidence in a determination ^[5].

The tools the MHRA holds

The agency's published position describes a range rather than a single sanction. It gives regulatory opinions and investigates complaints; it can issue a formal determination that a product is a medicine through a statutory procedure set out in its guidance; and it has authority to enforce the regulations covering medicinal products sold, supplied or advertised from within the UK ^{[4] [5]}. The Blue Guide sets out how the advertising provisions are applied, including to material that promotes an unauthorised product ^[6].

1. An informal request to amend or remove claims, which is where most borderline cases end ^[4].
2. A statutory determination that a named product is a medicinal product, after which continued supply without authorisation is a breach ^[5].
3. Action on advertising that promotes an unauthorised medicine, published in the monthly investigations series when concluded ^{[6] [7]}.
4. Criminal proceedings under the 2012 Regulations in serious or persistent cases ^[3].

The borderline guidance adds a caveat worth keeping in mind: it cannot be assumed that a product found to be in breach will automatically be removed from sale ^[4]. Enforcement is a process with stages, not a switch.

What the inquiry does not do

• It does not schedule or ban any substance. Scheduling is a Home Office matter under different legislation, and nothing in the reporting touches it.
• It does not authorise anything. No peptide became a licensed medicine because a regulator commented on it.
• It does not create a new rule for laboratory research. The presentation test existed before April 2026 and is applied the same way after it.
• It does not change what happens at the border. Customs control attaches to classification, and the reporting did not concern imports.

The confusion to avoid is reading an enforcement story about claims as a verdict on molecules. It is the substance-versus-product distinction again: the reported clinics were in trouble for how they presented a product and to whom, not because a sequence of amino acids became unlawful.

What changed for research supply

Legally, nothing. Practically, the tolerance for inconsistency fell, because a regulator has now said in public that research wording will be looked through where it is being used as cover ^[1]. The same point explains where the research-use-only phrase comes from and what it does not certify: it describes assessments that have not been made, and it cannot carry more weight than that.

It is equally important to say what the inquiry is not evidence of. Material supplied for laboratory research is not an alternative to the clinics that were reported, and it is not a lawful route to anything they were offering. It is a different product with a different purpose, and none of the regulator's statements say or imply otherwise.

1. Read a supplier's whole presentation — product page, label, invoice, certificate, social accounts — and check that it tells one research story throughout ^[5].
2. Treat any benefit language, testimonial or treatment-duration wording beside a research label as a contradiction the regulator would also notice ^[1].
3. Keep your own records in research terms: the purpose on a purchase order and in a lab register should match what the material is.
4. Watch the monthly advertising investigations for a concluded peptide case rather than relying on commentary ^[7].

For readers arriving from headlines, a general account of what a regulator's public notice is, and what it is not is a useful corrective before drawing conclusions about your own position from somebody else's enforcement story.

This article reports the public record as at 15 September 2026 and describes a regulatory framework. It is general reference material, not legal advice. If the inquiry produces published outcomes, they will appear first in the MHRA's own channels.